Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionCombination of oral Xeloda capecitabine and IV oxaliplatin
Molecular Target Thymidylate synthetase (TYMS) ; DNA
Mechanism of ActionBreaks/crosslinks DNA
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationColorectal cancer
Indication DetailsFirst-line treatment of metastatic colorectal cancer (mCRC); Treat metastatic colorectal cancer (mCRC); Treat stage III colon cancer following surgery
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today